Drug Profile
Ibrutinib companion diagnostic - Abbott/Janssen/Pharmacyclics
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Janssen Biotech; Pharmacyclics
- Developer Abbott Laboratories; Janssen Biotech; Pharmacyclics
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic lymphocytic leukaemia
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Chronic-lymphocytic-leukaemia(Diagnosis) in USA
- 26 May 2015 Pharmacyclics has been acquired by AbbVie
- 21 Feb 2013 Clinical trials in Chronic lymphocytic leukaemia (diagnosis) in USA (ex vivo)